Vaccination of ponies with the IE gene of EHV-1 in a recombinant modified live vaccinia vector protects against clinical and virological disease.

The research discusses a study where ponies were immunized with a vaccine containing the IE gene of EHV-1, a type of virus known to affect horses, which resulted in significant clinical protection from infection and a decrease in cell-associated viremia, a key requirement for preventing severe conditions like abortion and neurological disease.

Objectives and Importance of the Study

• The primary aim of this study was to control the EHV-1 (Equine herpesvirus type 1) infection in horses through effective vaccines that could stimulate virus-specific cytotoxic T-cell responses. These specialized immune system cells are crucial as they help reduce cell-associated viremia, a condition where viruses enter the bloodstream and spread throughout the body.
• However, current vaccines have not been efficient in invoking these essential responses. Therefore, the researchers turned toward the IE (Immediate Early) gene of EHV-1 that they identified as a potent stimulant of such responses in certain ponies.
• The study’s significant relevance lies in its potential to curtail EHV-1 infections which can lead to severe conditions in horses, like abortion and neurological diseases.

Execution of the Study

• The researchers selected ponies having a specific MHC (Major Histocompatibility Complex) class I serological haplotype A3/B2 for the study. They hypothesized the vaccination with the IE gene could shield these ponies and induce immune responses instrumental in cell-mediated immunity.
• The ponies were vaccinated with a recombinant modified vaccinia Ankara (rMVA) vector that expressed the IE gene. This was done in three phases, and they were subsequently exposed to an infection eight weeks post the final vaccination.
• The scientists analyzed IFN-gamma mRNA, which is crucial in immune response, and antibody titers over the duration of the study while monitoring the clinical signs, nasal virus shedding, and viremia post-infection.

Findings and Conclusion

• The study found that vaccination led to significant clinical protection in vaccinated ponies along with a marked decrease in EHV-1 viremia.
• In addition, they also witnessed a rise in IFN-gamma mRNA post-vaccination in the ponies. Antibody titers remained relatively low until after infection, which indicated no incidental field acquired or re-emerging EHV-1 infections occurred.
• These findings indicate that vaccination using the EHV-1 IE gene could be an effective strategy for inducing cytotoxic T-cell responses, thereby significantly reducing clinical disease and cell-associated viremia in horses.